AMN Healthcare Services vs Insperity
AMN and NSP side by side, both in personnel supply services. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AMN and NSP compare
Insperity is the larger company, worth 1.3 times as much as AMN Healthcare Services ($1.9B against $1.5B).
On earnings, AMN Healthcare Services is cheaper: it trades at 13.8× trailing earnings, against 556× for Insperity.
AMN Healthcare Services grew revenue faster over the last twelve months (29.5% versus 2.1% for Insperity).
AMN Healthcare Services keeps more of each dollar of sales as profit, with a net margin of 3.1% compared with 0.04% at Insperity.
Insperity pays a dividend yielding 4.8%; AMN Healthcare Services does not pay one.
AMN Healthcare Services scores higher on the StockData Score (14 against 9 for Insperity), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AMN | NSP |
|---|---|---|
| Size and price | ||
| Market cap | $1.5B | $1.9B |
| Share price | $37.90 | $50.08 |
| Change, 1 year | 118% | 52.5% |
| Change, 5 years | −68.0% | −57.4% |
| Beta (5Y) | 0.72 | 0.90 |
| Employees | 2,664 | 4,200 |
| StockData Score | ||
| Total score | 14 (better) | 9 |
| Valuation score | 5 (better) | 0 |
| Growth score | 1 | 1 |
| Performance score | 3 (better) | 1 |
| Health score | 5 (better) | 3 |
| Dividend score | 0 | 4 (better) |
| Valuation | ||
| P/E | 13.8× (better) | 556× |
| P/S | 0.4× | 0.3× (better) |
| P/B | 1.9× (better) | 43.4× |
| EV/EBITDA | 5.8× (better) | 27.4× |
| P/FCF | 4.5× (better) | 9.7× |
| FCF yield | 22.3% (better) | 10.3% |
| Fair value | $55.46 | $25.07 |
| Margin of safety | 31.7% (better) | −99.8% |
| Growth | ||
| Revenue growth (TTM) | 29.5% (better) | 2.1% |
| Revenue growth, 5Y average | 2.7% | 9.7% (better) |
| Net income growth (TTM) | – | −82.4% |
| EPS growth (TTM) | – | −79.5% |
| Profitability | ||
| Gross margin | 28.4% (better) | 13.0% |
| Operating margin | 5.8% (better) | 0.29% |
| Net margin | 3.1% (better) | 0.04% |
| FCF margin | 9.3% (better) | 2.9% |
| Return on equity | 15.4% (better) | 4.6% |
| Return on invested capital | 9.8% | – |
| Financial health | ||
| Debt / equity | 0.96 (better) | 9.52 |
| Net debt / EBITDA | 1.45 (better) | −2.86 |
| Interest coverage | 6.1× (better) | 0.8× |
| Current ratio | 1.21 (better) | 1.11 |
| Altman Z-score | 3.29 | 4.13 (better) |
| Piotroski F-score | 4 (better) | 1 |
| Dividends and buybacks | ||
| Dividend yield | – | 4.8% |
| Payout ratio | – | 3033% |
| Buyback yield | – | 0.52% |
| Shareholder yield | 0.00% | 5.3% (better) |
| Ownership | ||
| Held by institutions | 120% | 112% |
| Held by insiders | 0.87% | 6.8% |
| Insider net buying, 12 months | −$114K | $15.7M (better) |
| Superinvestors holding | 1 | 1 |
| Short interest, % of float | 11.1% | 7.8% |
Go deeper
- AMN stock overview
- AMN income statement
- AMN valuation and score
- NSP stock overview
- NSP income statement
- NSP valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.